SEC Filing Summary: Nile Therapeutics, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Nile Therapeutics, Inc. on March 13, 2008. The report serves to publicly disseminate financial results for the fourth quarter and the full fiscal year ended December 31, 2007. The filing references a press release attached as Exhibit 99.1 for detailed data.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and are not explicitly stated in the body of this 8-K form.
Material Changes
The filing does not detail specific material changes versus prior periods. It solely announces the release of the Q4 and full-year 2007 results.
Guidance, Outlook, and Risks
The document does not contain management commentary, future guidance, risk factors, or contingencies. It functions as a notification that the press release containing this information has been issued.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the attached press release (Exhibit 99.1).
- Confirm the company name discrepancy: The filing metadata lists "Capricor Therapeutics, Inc.," but the document text identifies the registrant as "Nile Therapeutics, Inc."
- Review the full text of the March 13, 2008 press release for operational updates and forward-looking statements.